Hainan Shuangcheng Pharmaceut
Hainan Shuangcheng Pharmaceuticals Co., Ltd. provides peptide, lyophilized, oncology, oral dosage, and other injection cartridge pharmaceutical products worldwide. The company offers thymalfasin, thymapentin, bortezmib, paclitaxel, somatostatin, pantoprazole, epifibatide, bivalirudin, liraglutide, and exenatide and sodium ferulate for injections, as well as vitamin B6. Hainan Shuangcheng Pharmace… Read more
Hainan Shuangcheng Pharmaceut (002693) - Total Assets
Latest total assets as of September 2025: CN¥797.77 Million CNY
Based on the latest financial reports, Hainan Shuangcheng Pharmaceut (002693) holds total assets worth CN¥797.77 Million CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hainan Shuangcheng Pharmaceut - Total Assets Trend (2009–2024)
This chart illustrates how Hainan Shuangcheng Pharmaceut’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hainan Shuangcheng Pharmaceut - Asset Composition Analysis
Current Asset Composition (December 2024)
Hainan Shuangcheng Pharmaceut's total assets of CN¥797.77 Million consist of 19.9% current assets and 80.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 5.8% |
| Accounts Receivable | CN¥26.56 Million | 3.4% |
| Inventory | CN¥80.54 Million | 10.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥175.02 Million | 22.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Hainan Shuangcheng Pharmaceut's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hainan Shuangcheng Pharmaceut's current assets represent 19.9% of total assets in 2024, a decrease from 32.5% in 2009.
- Cash Position: Cash and equivalents constituted 5.8% of total assets in 2024, down from 10.2% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 12.0% in 2009.
- Asset Diversification: The largest asset category is intangible assets at 22.3% of total assets.
Hainan Shuangcheng Pharmaceut Competitors by Total Assets
Key competitors of Hainan Shuangcheng Pharmaceut based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Hainan Shuangcheng Pharmaceut - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Hainan Shuangcheng Pharmaceut generates 0.22x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Hainan Shuangcheng Pharmaceut is currently not profitable relative to its asset base.
Hainan Shuangcheng Pharmaceut - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.86 | 1.00 | 1.53 |
| Quick Ratio | 0.45 | 0.49 | 1.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-28.37 Million | CN¥ -675.01K | CN¥ 68.09 Million |
Hainan Shuangcheng Pharmaceut - Advanced Valuation Insights
This section examines the relationship between Hainan Shuangcheng Pharmaceut's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.74 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | -2.4% |
| Total Assets | CN¥783.87 Million |
| Market Capitalization | $222.90 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hainan Shuangcheng Pharmaceut's assets below their book value (0.28 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Hainan Shuangcheng Pharmaceut's assets decreased by 2.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Hainan Shuangcheng Pharmaceut (2009–2024)
The table below shows the annual total assets of Hainan Shuangcheng Pharmaceut from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥783.87 Million | -2.41% |
| 2023-12-31 | CN¥803.25 Million | -11.83% |
| 2022-12-31 | CN¥911.02 Million | +6.61% |
| 2021-12-31 | CN¥854.56 Million | -5.85% |
| 2020-12-31 | CN¥907.68 Million | -4.55% |
| 2019-12-31 | CN¥950.98 Million | -15.11% |
| 2018-12-31 | CN¥1.12 Billion | -18.65% |
| 2017-12-31 | CN¥1.38 Billion | +18.15% |
| 2016-12-31 | CN¥1.17 Billion | -24.81% |
| 2015-12-31 | CN¥1.55 Billion | +64.29% |
| 2014-12-31 | CN¥943.54 Million | +2.89% |
| 2013-12-31 | CN¥917.04 Million | +3.43% |
| 2012-12-31 | CN¥886.65 Million | +257.44% |
| 2011-12-31 | CN¥248.06 Million | -1.85% |
| 2010-12-31 | CN¥252.73 Million | +158.28% |
| 2009-12-31 | CN¥97.85 Million | -- |